212 related articles for article (PubMed ID: 10962569)
1. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.
Ge NL; Rudikoff S
Oncogene; 2000 Aug; 19(36):4091-5. PubMed ID: 10962569
[TBL] [Abstract][Full Text] [Related]
2. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
3. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
4. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
6. Loss of PTEN expression leading to high Akt activation in human multiple myelomas.
Hyun T; Yam A; Pece S; Xie X; Zhang J; Miki T; Gutkind JS; Li W
Blood; 2000 Nov; 96(10):3560-8. PubMed ID: 11071655
[TBL] [Abstract][Full Text] [Related]
7. A surprising function for the PTEN tumor suppressor.
Hopkin K
Science; 1998 Nov; 282(5391):1027,1029-30. PubMed ID: 9841444
[No Abstract] [Full Text] [Related]
8. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes.
Ono H; Katagiri H; Funaki M; Anai M; Inukai K; Fukushima Y; Sakoda H; Ogihara T; Onishi Y; Fujishiro M; Kikuchi M; Oka Y; Asano T
Mol Endocrinol; 2001 Aug; 15(8):1411-22. PubMed ID: 11463863
[TBL] [Abstract][Full Text] [Related]
9. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
10. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1.
Bruni P; Boccia A; Baldassarre G; Trapasso F; Santoro M; Chiappetta G; Fusco A; Viglietto G
Oncogene; 2000 Jun; 19(28):3146-55. PubMed ID: 10918569
[TBL] [Abstract][Full Text] [Related]
11. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.
Dahia PL; Aguiar RC; Alberta J; Kum JB; Caron S; Sill H; Marsh DJ; Ritz J; Freedman A; Stiles C; Eng C
Hum Mol Genet; 1999 Feb; 8(2):185-93. PubMed ID: 9931326
[TBL] [Abstract][Full Text] [Related]
12. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
Haas-Kogan D; Shalev N; Wong M; Mills G; Yount G; Stokoe D
Curr Biol; 1998 Oct; 8(21):1195-8. PubMed ID: 9799739
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN facilitates HIF-1-mediated gene expression.
Zundel W; Schindler C; Haas-Kogan D; Koong A; Kaper F; Chen E; Gottschalk AR; Ryan HE; Johnson RS; Jefferson AB; Stokoe D; Giaccia AJ
Genes Dev; 2000 Feb; 14(4):391-6. PubMed ID: 10691731
[TBL] [Abstract][Full Text] [Related]
15. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.
Wu X; Senechal K; Neshat MS; Whang YE; Sawyers CL
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15587-91. PubMed ID: 9861013
[TBL] [Abstract][Full Text] [Related]
16. PTEN expression causes feedback upregulation of insulin receptor substrate 2.
Simpson L; Li J; Liaw D; Hennessy I; Oliner J; Christians F; Parsons R
Mol Cell Biol; 2001 Jun; 21(12):3947-58. PubMed ID: 11359902
[TBL] [Abstract][Full Text] [Related]
17. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K; Zhou XP; Araki T; Cannistra SA; Maher ER; Eng C
Am J Pathol; 2001 Jun; 158(6):2097-106. PubMed ID: 11395387
[TBL] [Abstract][Full Text] [Related]
18. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
19. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
20. PTEN/MMAC1 overexpression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells.
van Golen CM; Schwab TS; Ignatoski KM; Ethier SP; Feldman EL
Cell Growth Differ; 2001 Jul; 12(7):371-8. PubMed ID: 11457734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
